BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23996115)

  • 21. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
    Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
    Hu S; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
    Chang HY; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties.
    Hu S; Datta-Mannan A; D'Argenio DZ
    MAbs; 2022; 14(1):2056944. PubMed ID: 35491902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
    Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
    MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of Minimal Physiologically Based Pharmacokinetic Models for Assessing Fractional Distribution, Oral Absorption, and Series-Compartment Models of Hepatic Clearance.
    Li X; Jusko WJ
    Drug Metab Dispos; 2023 Oct; 51(10):1403-1418. PubMed ID: 37460222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley Rats.
    Hardiansyah D; Ng CM
    Pharm Res; 2022 Mar; 39(3):481-496. PubMed ID: 35246757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically Based Pharmacokinetic (PBPK) Models II: Practical Application of Tissue Lumping Theories for Pharmacokinetics of Various Compounds.
    Jeong YS; Kim MS; Chung SJ
    AAPS J; 2022 Aug; 24(5):91. PubMed ID: 36002779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution.
    Conner KP; Rock BM; Kwon GK; Balthasar JP; Abuqayyas L; Wienkers LC; Rock DA
    Drug Metab Dispos; 2014 Nov; 42(11):1906-13. PubMed ID: 25209366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.
    Wang-Lin SX; Zhou C; Kamath AV; Hong K; Koppada N; Saad OM; Carrasco-Triguero M; Khojasteh C; Deng R
    MAbs; 2018 Oct; 10(7):1131-1143. PubMed ID: 30081725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
    Li L; Gardner I; Dostalek M; Jamei M
    AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
    Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P
    Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.
    Shah DK; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):55-69. PubMed ID: 24368689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.
    Shah DK; Betts AM
    MAbs; 2013; 5(2):297-305. PubMed ID: 23406896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.
    Patidar K; Pillai N; Dhakal S; Avery LB; Mavroudis PD
    J Pharmacokinet Pharmacodyn; 2024 Feb; ():. PubMed ID: 38400996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations.
    Puszkiel A; Bousquet G; Stanke-Labesque F; Stocco J; Decq P; Chevillard L; Goutagny S; Declèves X
    Pharm Res; 2023 Nov; 40(11):2687-2697. PubMed ID: 37821769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
    Glassman PM; Balthasar JP
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms.
    De Sutter PJ; Gasthuys E; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2023 Nov; ():. PubMed ID: 37952005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.